ImmunityBio is a clinical-stage biotechnology company developing therapies and vaccines that complement, harness, and amplify the immune system to defeat cancers and infectious diseases. Co.'s platforms include: antibody cytokine fusion proteins, which include Anktiva, a class of biopharmaceuticals that improve the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response; and DNA, RNA, and recombinant protein vaccine technologies, which are for infectious diseases to target key viruses, including coronavirus, and for oncology to deliver tumor-associated antigens, and neoepitopes (expressed only by cancer cells).
IBRX — Key Stats (updated Friday, March 31, 10:44 AM)